Device Trial Radar · NCT06480227
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
358
Planned (sponsor's estimate)
Start
Aug 28, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- NICHD Pelvic Floor Disorders NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- Duke University; Kaiser Permanente; University of Chicago; University of Pennsylvania; University of Texas Southwestern Medical Center; Women and Infants Hospital of Rhode Island; RTI International; University of California, San Diego; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Jun 28, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care. The Primary Aim is to determine the comparative effectiveness (as defined by "much" or "very much" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).
Conditions
- Stress Urinary Incontinence
- Urinary Incontinence
- Mixed Urinary Incontinence
Interventions
Solyx Single-incision SlingDevice
Minimally invasive mesh device placed to treat stress urinary incontinence.
Bulkamid Transurethral Bulking AgentDevice
Minimally invasive bulking agent injections used to bulk up the tissue surrounding the urethra to treat stress urinary incontinence. Up to 2 treatments within 12 months are allowed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjective success measured by Patient Global Impression-Improvement [PGI-I] (>2) for TBA vs. SIS at 12 months.Time frame: At 12 months post-intervention.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of California at San Diego
La Jolla, California · Recruiting
Kaiser Permanente -- San Diego
San Diego, California · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.